Detalles de la búsqueda
1.
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program.
Pharmacoepidemiol Drug Saf
; 33(5): e5799, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38680102
2.
Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.
Eur J Clin Pharmacol
; 74(2): 193-199, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29134254
3.
Off-hours admission and quality of hip fracture care: a nationwide cohort study of performance measures and 30-day mortality.
Int J Qual Health Care
; 28(3): 324-31, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27097886
4.
Off-hours admission and acute stroke care quality: a nationwide study of performance measures and case-fatality.
Stroke
; 45(12): 3663-9, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25378421
5.
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.
Clin Drug Investig
; 42(4): 319-331, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35290649
6.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Drug Saf
; 44(8): 899-915, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34236595
7.
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Curr Med Res Opin
; 37(5): 867-877, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33591859
8.
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
PLoS One
; 13(9): e0204456, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30260993
Resultados
1 -
8
de 8
1
Próxima >
>>